Krystal Biotech (KRYS) Interest Expenses (2016 - 2026)

Krystal Biotech (KRYS) has 11 years of Interest Expenses data on file, last reported at $286.1 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 43.91% year-over-year to $286.1 million; the trailing twelve-month figure through Mar 2026 stood at $286.1 million (up 43.91% YoY), and the FY2025 full-year result was $298.7 million, up 90.96% from the prior year.
• Interest Expenses eased to $286.1 million in Q1 2026, from $298.7 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $298.7 million in Q4 2025 to a low of $28.3 million in Q2 2022.
• A 5-year average of $157.4 million and a median of $162.8 million in 2023 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses soared 496.74% in 2023 and sank 46.65% in 2025, its largest moves.
• Tracing KRYS's Interest Expenses over 5 years: stood at $37.2 million in 2022, then jumped by 304.17% to $150.4 million in 2023, then climbed by 3.99% to $156.4 million in 2024, then jumped by 90.96% to $298.7 million in 2025, then declined by 4.2% to $286.1 million in 2026.
• Business Quant data shows KRYS's Interest Expenses at $286.1 million in Q1 2026, $298.7 million in Q4 2025, and $180.4 million in Q3 2025.